6.90
—
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mega Genomics
Its shares trade on HKEX under the ticker 6667.HK. It has been listed since 22 June 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥288.3m and net income of CN¥30.7m. At that date it held total assets of CN¥971.0m and shareholders' equity of CN¥712.7m.
Mega Genomics Ltd. operates as a genetic testing platform company, which engages in consumer genetic testing and cancer screening services. The company is headquartered in Beijing, Beijing. The company went IPO on 2022-06-22. The firm operates its businesses through three segments. The Consumer Genetic Testing Services segment provides testing for nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, pharmacogenetic testing and infectious disease testing. The Cancer Screening Services segment provides Septin9 colorectal cancer screening test, Syndecan-2 (SDC2) colorectal cancer screening test and ring finger protein 180 (RNF180)/Septin9 gastric cancer screening test. The Other Services segment provides genetic research and analysis services to third party research institutions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 22 Jun 2022
- Employees
- 267
- Website
- megagenomics.cn ↗
Leadership
Pay as last reported
- Ms. Lin LinExecutive Chairman of the Board, since 2021
- Ms. Jing JiangChief Financial Officer, Executive Director, since 2020
- Dr. Rong YuExecutive Director, Honorary Co-Chairperson, since 2021
- Dr. Xia AnHead - Operations
- Dr. Xiani GongHead - Branding
- Mr. Cong LiHead - Information Technology
- Dr. Xiang YiHead - Research and Development
- Ms. Wai Kam NgCompany Secretary
- Ms. Meiling GuoNon-Executive Director, Honorary Co-Chairperson
- Mr. Qingfeng JiaNon-Executive Independent Director
- Dr. Dan XieNon-Executive Independent Director
- Mr. Ying ZhangNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Operates as a genetic testing platform company with three business segments.
- Provides consumer genetic testing and cancer screening services in Beijing.
- Has an IPO date of 2022-06-22 and 267 employees.
Weaknesses
- No specific weaknesses mentioned in the provided information.
- Operates in a highly regulated health care sector.
- Relies on three business segments without additional details on performance.
Opportunities
- Expands consumer genetic testing and cancer screening services in the health care sector.
- Potential for growth in genetic research and analysis services to third parties.
- IPO in 2022 may attract further investment and market expansion.
Threats
- Operates in a highly regulated health care sector with potential compliance challenges.
- Dependence on specific cancer screening tests without mention of alternatives.
- No information on market competition or industry trends provided.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.